Sugi Predict

Sugi Predict / Compounds / SCHEMBL6163681

SCHEMBL6163681

SCHEMBL6163681

NC(=O)c1cc[nH]c(=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PARP1 P09874 7/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ CDK7 P50613 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ CCNH P51946 1/20 0.41
▸ MNAT1 P51948 1/20 0.41
▸ CDK6 Q00534 1/20 0.41
▸ PRKCI P41743 1/20 0.40
▸ LCK P06239 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1255885 0.80 MEN1 (0.56) MEN1KMT2ANOTUMHSD17B10TSHR
SCHEMBL3630779 0.80 PARP1 (0.51) MEN1KMT2APARP1POLB
SCHEMBL2291968 0.78 KMT2A (0.41) MEN1KMT2ANOTUMHSD17B10TSHR
SCHEMBL11706244 0.78 SLC2A1 (0.46) MEN1KMT2ANOTUMCDK8CDK7
SCHEMBL4394829 0.78 RECQL (0.39) MEN1KMT2ANOTUMCYP3A4MAPT
SCHEMBL872464 0.78 RECQL (0.39) MEN1KMT2ANOTUMCYP3A4MAPT
SCHEMBL2896727 0.78 ALDH1A1 (0.47) MEN1KMT2APOLBCYP3A4MAPT
SCHEMBL2903920 0.75 MEN1 (0.40) MEN1KMT2ANOTUMMAPTBRD4
SCHEMBL13729839 0.74 HDAC8 (0.47) CDK8TSHRAPOBEC3GSMN1; SMN2SMYD3
SCHEMBL205408 0.74 CA1 (0.48) MEN1KMT2APARP1CDK8HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119698278-A Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases 斯克里普斯研究学院 2025-03-25 — — CN claimed
US-11724999-B2 Inhibitors of RAS-effector protein interactions OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-08-15 — — US claimed
US-20210047305-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-02-18 — — US claimed
EP-2507243-A1 SPIROINDOLINONE PYRROLIDINES F. Hoffmann-La Roche AG (CH) 2012-10-10 — — EP claimed
CN-119698278-A Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases 斯克里普斯研究学院 2025-03-25 — — CN disclosed
CN-119320386-A METTL3 inhibitor, preparation method and application thereof 郑州大学第一附属医院 2025-01-17 — — CN disclosed
WO-2025011476-A1 INDAZOLE DERIVATIVE OR PHARMACEUTICAL SALT THEREOF AND USE THEREOF 浙江大学 2025-01-16 — — WO disclosed
CN-119219609-A Indazole derivative or pharmaceutically acceptable salt thereof and application thereof 浙江大学 2024-12-31 — — CN disclosed
CN-112839942-B 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社 钟根堂 2024-08-23 — — CN disclosed
CN-116891460-A Indazole derivative or pharmaceutically acceptable salt thereof and application thereof 浙江大学 2023-10-17 — — CN disclosed
EP-4249480-A1 DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Northwest A&F University (CN) 2023-09-27 — — EP disclosed
US-11724999-B2 Inhibitors of RAS-effector protein interactions OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-08-15 — — US disclosed
EP-2285783-B1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-21 — — EP disclosed
EP-2507243-A1 SPIROINDOLINONE PYRROLIDINES F. Hoffmann-La Roche AG (CH) 2012-10-10 — — EP disclosed
US-8263597-B2 Indazole compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-11 — — US disclosed
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 — — US disclosed
EP-1448196-B1 BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2005-10-12 — — EP disclosed
EP-1448196-A1 BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. Hoffmann-La Roche AG (CH) 2004-08-25 — — EP disclosed
US-6599901-B1 Adenosine receptor ligands used in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease HOFFMAN-LA ROCHE INC. 2003-07-29 — — US disclosed
WO-2003043634-A1 BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCRL2 MEN1 3253/4885KMT2A 4336/4885PARP1 1910/4885
US-20210047305-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS KRAS, NRAS, HRAS MEN1 860/4885KMT2A 3937/4885PARP1 3580/4885
US-11724999-B2 Inhibitors of RAS-effector protein interactions KRAS, NRAS, HRAS MEN1 860/4885KMT2A 3937/4885PARP1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.